, Volume 191, Issue 4, pp 369–377 | Cite as

The Association Between TP53 Arg72Pro Polymorphism and Lung Cancer Susceptibility: Evidence from 30,038 Subjects

  • Qian Qiao
  • Weiguo Hu



The TP53 codon 72 polymorphism has been associated with the individual susceptibility to lung cancer. However, the association remains uncertain and varies with ethnicity, smoking status, cancer histology, and stage.


We performed a meta-analysis to evaluate the relationship between TP53 Arg72Pro polymorphism and lung cancer susceptibility basing on 15,647 lung cancer patients and 14,391 controls from 36 published literatures. We also performed stratified analysis in populations of different ethnicities, smoking statuses, lung cancer stages, and histological types.


The analysis showed a significantly increased lung cancer susceptibility among Pro allele carriers (P < 0.001, odds ratio (OR) = 1.14, 95 % confidence interval (CI) = 1.1–1.19), especially for smokers (P < 0.001, OR = 1.29, 95 % CI = 1.12–1.47). Stratified analysis indicated that Pro72 elevates lung cancer susceptibility in Asians, while it has no effect on lung cancer risk of Caucasians. Moreover, Pro carriers present an increased risk of developing squamous cell carcinoma and adenocarcinoma, instead of large cell carcinoma and small cell carcinoma. Interestingly, patients with the Pro allele seemed to be diagnosed with lung cancer at the early stages (stage I–II, P = 0.008, OR = 1.2, 95 % CI = 1.05–1.37).


Our results suggest that the Pro allele acts as a risk factor for development of lung cancer, especially for smokers and Asians.


TP53 Arg72Pro Lung cancer Meta-analysis 


Conflict of interest



  1. 1.
    Lichtenstein P, Holm N, Verkasalo P, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K (2000) Environmental and heritable factors in the causation of cancer–analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343:78PubMedCrossRefGoogle Scholar
  2. 2.
    Zhang D, Chen C, Li Y, Fu X, Xie Y, Li Y, Huang Y (2012) Cx31. 1 acts as a tumour suppressor in non-small cell lung cancer (NSCLC) cell lines through inhibition of cell proliferation and metastasis. J Cell Mol Med 16:1047–1059PubMedCrossRefGoogle Scholar
  3. 3.
    Zhang D, Chen C, Fu X, Gu S, Mao Y, Xie Y, Huang Y, Li Y (2008) A meta-analysis of DNA repair gene XPC polymorphisms and cancer risk. J Hum Genet 53:18–33PubMedCrossRefGoogle Scholar
  4. 4.
    Oren M (2003) Decision making by p53: life, death and cancer. Cell Death Differ 10:431–442PubMedCrossRefGoogle Scholar
  5. 5.
    Lane D (2004) p53 from pathway to therapy. Carcinogenesis 25:1077PubMedCrossRefGoogle Scholar
  6. 6.
    Vogelstein B, Lane D, Levine A (2000) Surfing the p53 network. Nature 408:307–310PubMedCrossRefGoogle Scholar
  7. 7.
    Murphy M (2006) Polymorphic variants in the p53 pathway. Cell Death Differ 13:916–920PubMedCrossRefGoogle Scholar
  8. 8.
    Pietsch E, Humbey O, Murphy M (2006) Polymorphisms in the p53 pathway. Oncogene 25:1602–1611PubMedCrossRefGoogle Scholar
  9. 9.
    Dumont P, Leu JIJ, Della Pietra AC, George DL, Murphy M (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33:357–365PubMedCrossRefGoogle Scholar
  10. 10.
    Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G (1999) Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 19:1092–1100PubMedGoogle Scholar
  11. 11.
    Pim D, Banks L (2004) p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 108:196–199PubMedCrossRefGoogle Scholar
  12. 12.
    Cavallone L, Arcand SL, Maugard C, Ghadirian P, Mes-Masson AM, Provencher D, Tonin PN (2008) Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent. BMC Cancer 8:96PubMedCrossRefGoogle Scholar
  13. 13.
    Woolf B (1955) On estimating the relation between blood group and disease. Ann Hum Genet 19:251–253PubMedCrossRefGoogle Scholar
  14. 14.
    Lau J, Ioannidis JP, Schmid CH (1997) Quantitative synthesis in systematic reviews. Ann Intern Med 127:820–826PubMedCrossRefGoogle Scholar
  15. 15.
    Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634PubMedCrossRefGoogle Scholar
  16. 16.
    Weston A, Ling-Cawley HM, Caporaso NE, Bowman ED, Hoover RN, Trump BF, Harris CC (1994) Determination of the allelic frequencies of an L-myc and a p53 polymorphism in human lung cancer. Carcinogenesis 15:583PubMedCrossRefGoogle Scholar
  17. 17.
    Miller DP, Liu G, De Vivo I, Lynch TJ, Wain JC, Su L, Christiani DC (2002) Combinations of the variant genotypes of GSTP1, GSTM1, and p53 are associated with an increased lung cancer risk. Cancer Res 62:2819PubMedGoogle Scholar
  18. 18.
    Papadakis ED, Soulitzis N, Spandidos DA (2002) Association of p53 codon 72 polymorphism with advanced lung cancer: the Arg allele is preferentially retained in tumours arising in Arg/Pro germline heterozygotes. Br J Cancer 87:1013–1018PubMedCrossRefGoogle Scholar
  19. 19.
    Wu X, Zhao H, Amos CI, Shete S, Makan N, Hong WK, Kadlubar FF, Spitz MR (2002) p53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Natl Cancer Inst 94:681PubMedCrossRefGoogle Scholar
  20. 20.
    Nadji SA, Mahmoodi M, Ziaee AA, Naghshvar F, Torabizadeh J, Yahyapour Y, Nategh R, Mokhtari-Azad T (2007) An increased lung cancer risk associated with codon 72 polymorphism in the TP53 gene and human papillomavirus infection in Mazandaran province, Iran. Lung Cancer 56:145–151PubMedCrossRefGoogle Scholar
  21. 21.
    Biros E, Kalina I, Biros I, Kohut A, Bogyiova E, Salagovic J, Stubna J (2001) Polymorphism of the p53 gene within the codon 72 in lung cancer patients. Neoplasma 48:407–411PubMedGoogle Scholar
  22. 22.
    Fan R, Wu MT, Miller D, Wain JC, Kelsey KT, Wiencke JK, Christiani DC (2000) The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 9:1037PubMedGoogle Scholar
  23. 23.
    Murata M, Tagawa M, Kimura M, Kimura H, Watanabe S, Saisho H (1996) Analysis of a germ line polymorphism of the p53 gene in lung cancer patients; discrete results with smoking history. Carcinogenesis 17:261PubMedCrossRefGoogle Scholar
  24. 24.
    Biro E, Kalina I, Kohút A (2001) Germ line polymorphisms of the tumor suppressor gene p53 and lung cancer. Lung Cancer 31:157–162CrossRefGoogle Scholar
  25. 25.
    Murata M, Tagawa M, Kimura H, Kakisawa K, Shirasawa H, Fujisawa T (1998) Correlation of the mutation of p53 gene and the polymorphism at codon 72 in smoking-related non-small cell lung cancer patients. Int J Oncol 12:577PubMedGoogle Scholar
  26. 26.
    Weston A, Perrin LS, Forrester K, Hoover RN, Trump BF, Harris CC, Caporaso NE (1992) Allelic frequency of a p53 polymorphism in human lung cancer. Cancer Epidemiol Biomarkers Prev 1:481PubMedGoogle Scholar
  27. 27.
    Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi SI (1993) Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis 14:1085PubMedCrossRefGoogle Scholar
  28. 28.
    Birgander R, Sjlander A, Rannug A, Alexandrie AK, Sundberg MI, Seideg J, Tornling G, Beckman G, Beckman L (1995) P53 polymorphisms and haplotypes in lung cancer. Carcinogenesis 16:2233PubMedCrossRefGoogle Scholar
  29. 29.
    Jin X, Wu X, Roth JA, Amos CI, King TM, Branch C, Honn SE, Spitz MR (1995) Higher lung cancer risk for younger African-Americans with the Pro/Pro p53 genotype. Carcinogenesis 16:2205PubMedCrossRefGoogle Scholar
  30. 30.
    To-Figueras J, Gene M, Gomez-Catalan J, Galan C, Firvida J, Fuentes M, Rodamilans M, Huguet E, Estape J, Corbella J (1996) Glutathione-S-Transferase M1 and codon 72 p53 polymorphisms in a northwestern Mediterranean population and their relation to lung cancer susceptibility. Cancer Epidemiol Biomarkers Prev 5:337PubMedGoogle Scholar
  31. 31.
    Wang YC, Chen CY, Chen SK, Chang YY, Lin P (1999) p53 codon 72 polymorphism in Taiwanese lung cancer patients: association with lung cancer susceptibility and prognosis. Clin Cancer Res 5:129PubMedGoogle Scholar
  32. 32.
    Pierce LM, Sivaraman L, Chang W, Lum A, Donlon T, Seifried A, Wilkens LR, Lau AF, Le Marchand L (2000) Relationships of TP53 codon 72 and HRAS1 polymorphisms with lung cancer risk in an ethnically diverse population. Cancer Epidemiol Biomarkers Prev 9:1199PubMedGoogle Scholar
  33. 33.
    Liu G, Miller DP, Zhou W, Thurston SW, Fan R, Xu LL, Lynch TJ, Wain JC, Su L, Christiani DC (2001) Differential association of the codon 72 p53 and GSTM1 polymorphisms on histological subtype of non-small cell lung carcinoma. Cancer Res 61:8718PubMedGoogle Scholar
  34. 34.
    Hiraki A, Matsuo K, Hamajima N, Ito H, Hatooka S, Suyama M, Mitsudomi T, Tajima K (2003) Different risk relations with smoking for non-small-cell lung cancer: comparison of TP53 and TP73 genotypes. Asian Pac J Cancer Prev 4:107–112PubMedGoogle Scholar
  35. 35.
    Irarrázabal CE, Rojas C, Aracena R, Márquez C, Gil L (2003) Chilean pilot study on the risk of lung cancer associated with codon 72 polymorphism in the gene of protein p53. Toxicol Lett 144:69–76PubMedCrossRefGoogle Scholar
  36. 36.
    Zhang JH, Li Y, Wang R, Wen DG, Wu ML, He M (2003) p53 gene polymorphism with susceptibility to esophageal cancer and lung cancer in Chinese population. Zhonghua Zhong Liu Za Zhi [Chinese J Oncol] 25:365Google Scholar
  37. 37.
    Jain N, Singh V, Hedau S, Kumar S, Daga MK, Dewan R, Murthy NS, Husain SA, Das BC (2005) Infection of human papillomavirus type 18 and p53 codon 72 polymorphism in lung cancer patients from India. Chest 128:3999PubMedCrossRefGoogle Scholar
  38. 38.
    Sakiyama T, Kohno T, Mimaki S, Ohta T, Yanagitani N, Sobue T, Kunitoh H, Saito R, Shimizu K, Hirama C (2005) Association of amino acid substitution polymorphisms in DNA repair genes TP53, POLI, REV1 and LIG4 with lung cancer risk. Int J Cancer 114:730–737PubMedCrossRefGoogle Scholar
  39. 39.
    Szymanowska A, Jassem E, Dziadziuszko R, Borg A, Limon J, Kobierska-Gulida G, Rzyman W, Jassem J (2006) Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism. Lung Cancer 52:9–14PubMedCrossRefGoogle Scholar
  40. 40.
    Zhang X, Miao X, Guo Y, Tan W, Zhou Y, Sun T, Wang Y, Lin D (2006) Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum Mutat 27:110–117PubMedCrossRefGoogle Scholar
  41. 41.
    Giuliani L, Jaxmar T, Casadio C, Gariglio M, Manna A, D’Antonio D, Syrjanen K, Favalli C, Ciotti M (2007) Detection of oncogenic viruses (SV40, BKV, JCV, HCMV, HPV) and p53 codon 72 polymorphism in lung carcinoma. Lung Cancer 57:273–281PubMedCrossRefGoogle Scholar
  42. 42.
    Mechanic LE, Bowman ED, Welsh JA, Khan MA, Hagiwara N, Enewold L, Shields PG, Burdette L, Chanock S, Harris CC (2007) Common genetic variation in TP53 is associated with lung cancer risk and prognosis in African Americans and somatic mutations in lung tumors. Cancer Epidemiol Biomarkers Prev 16:214PubMedCrossRefGoogle Scholar
  43. 43.
    Popanda O, Edler L, Waas P, Schattenberg T, Butkiewicz D, Muley T, Dienemann H, Risch A, Bartsch H, Schmezer P (2007) Elevated risk of squamous-cell carcinoma of the lung in heavy smokers carrying the variant alleles of the TP53 Arg72Pro and p21 Ser31Arg polymorphisms. Lung Cancer 55:25–34PubMedCrossRefGoogle Scholar
  44. 44.
    Honma HN, De Capitani EM, Perroud MW Jr, Barbeiro AS, Toro IFC, Costa DB, Lima CSP, Zambon L (2008) Influence of p53 codon 72 exon 4, GSTM1, GSTT1 and GSTP1* B polymorphisms in lung cancer risk in a Brazilian population. Lung Cancer 61:152–162PubMedCrossRefGoogle Scholar
  45. 45.
    Jung HY, Whang YM, Sung JS, Shin HD, Park BL, Kim JS, Shin SW, Seo HY, Seo JH, Kim YH (2008) Association study of TP53 polymorphisms with lung cancer in a Korean population. J Hum Genet 53:508–514PubMedCrossRefGoogle Scholar
  46. 46.
    Fernández-Rubio A, López-Cima MF, González-Arriaga P, García-Castro L, Pascual T, Marrón MG, Tardón A (2008) The TP53 Arg72Pro polymorphism and lung cancer risk in a population of Northern Spain. Lung Cancer 61:309–316PubMedCrossRefGoogle Scholar
  47. 47.
    Sreeja L, Syamala V, Raveendran PB, Santhi S, Madhavan J, Ankathil R (2008) p53 Arg72Pro polymorphism predicts survival outcome in lung cancer patients in Indian population. Cancer Invest 26:41–46PubMedCrossRefGoogle Scholar
  48. 48.
    Cáceres DD, Qui ones LA, Schroeder JC, Gil LD, Irarrázabal CE (2009) Association Between p53 codon 72 genetic polymorphism and tobacco use and lung cancer risk. Lung 187:110–115PubMedCrossRefGoogle Scholar
  49. 49.
    Klinchid J, Chewaskulyoung B, Saeteng S, Lertprasertsuke N, Kasinrerk W, Cressey R (2009) Effect of combined genetic polymorphisms on lung cancer risk in northern Thai women. Cancer Genet Cytogenet 195:143–149PubMedCrossRefGoogle Scholar
  50. 50.
    Sobti RC, Kaur P, Kaur S, Janmeja AK, Jindal SK, Kishan J, Raimondi S (2009) Impact of interaction of polymorphic forms of p53 Codon 72 and N-acetylation gene (NAT2) on the risk of lung cancer in the North Indian population. DNA Cell Biol 28:443–449PubMedCrossRefGoogle Scholar
  51. 51.
    Chua HW, Ng D, Choo S, Lum SS, Li H, Soh LY, Sabapathy K, Seow A (2010) Effect of MDM 2 SNP 309 and p 53 codon 72 polymorphisms on lung cancer risk and survival among non-smoking Chinese women in Singapore. BMC Cancer 10:88PubMedCrossRefGoogle Scholar
  52. 52.
    Ihsan R, Devi TR, Yadav DS, Mishra AK, Sharma J, Zomawia E, Verma Y, Phukan R, Mahanta J, Kataki AC (2011) Investigation on the role of p53 codon 72 polymorphism and interactions with tobacco, Betel Quid, and alcohol in susceptibility to cancers in a high-risk population from North East India. DNA Cell Biol 30:317–324Google Scholar
  53. 53.
    Su L, Sai Y, Fan R, Thurston SW, Miller DP, Zhou W, Wain JC, Lynch TJ, Liu G, Christiani DC (2003) P53 (codon 72) and P21 (codon 31) polymorphisms alter in vivo mRNA expression of p21. Lung Cancer 40:259–266PubMedCrossRefGoogle Scholar
  54. 54.
    Hung RJ, Boffetta P, Canzian F, Moullan N, Szeszenia-Dabrowska N, Zaridze D, Lissowska J, Rudnai P, Fabianova E, Mates D (2006) Sequence variants in cell cycle control pathway, X-ray exposure, and lung cancer risk: a multicenter case-control study in Central Europe. Cancer Res 66:8280–8286PubMedCrossRefGoogle Scholar
  55. 55.
    Cherdyntseva N, Gervas P, Litvyakov N, Stakcheeva M, Ponomaryeva A, Dobrodeev AY, Denisov E, Belyavskaya V, Choinzonov E (2010) Age-related function of tumor suppressor gene TP53: contribution to cancer risk and progression. Exp Oncol 32:205–208PubMedGoogle Scholar
  56. 56.
    Kiyohara C, Horiuchi T, Miyake Y, Takayama K, Nakanishi Y (2010) Cigarette smoking, TP53 Arg72Pro, TP53BP1 Asp353Glu and the risk of lung cancer in a Japanese population. Oncol Rep 23:1361PubMedCrossRefGoogle Scholar
  57. 57.
    Piao JM, Kim HN, Song HR, Kweon SS, Choi JS, Yun WJ, Kim YC, Oh IJ, Kim KS, Shin MH (2011) p53 codon 72 polymorphism and the risk of lung cancer in a Korean population. Lung Cancer 73:264–267PubMedCrossRefGoogle Scholar
  58. 58.
    Liu D, Wang F, Guo X, Wang Q, Wang W, Xu H, Xu G (2012) Association between p53 codon 72 genetic polymorphisms and tobacco use and lung cancer risk in a Chinese population. Mol Biol Rep 40:1–5Google Scholar
  59. 59.
    Cheng Z, Wang W, Song YN, Kang Y, Xia J (2012) hOGG1, p53 genes, and smoking interactions are associated with the development of lung cancer. Asian Pac J Cancer Prev 13(5):1803–1808PubMedCrossRefGoogle Scholar
  60. 60.
    Chen C, Fu X, Zhang D, Li Y, Xie Y, Li Y, Huang Y (2011) Varied pathways of stage IA lung adenocarcinomas discovered by integrated gene expression analysis. Int J Biol Sci 7:551PubMedCrossRefGoogle Scholar
  61. 61.
    Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science 253:49–53PubMedCrossRefGoogle Scholar
  62. 62.
    Dumont P, Leu J, Della Pietra A, George D, Murphy M (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nature Genet 33:357–365PubMedCrossRefGoogle Scholar
  63. 63.
    Dai S, Mao C, Jiang L, Wang G, Cheng H (2009) P53 polymorphism and lung cancer susceptibility: a pooled analysis of 32 case–control studies. Hum Genet 125:633–638PubMedCrossRefGoogle Scholar
  64. 64.
    Li Y, Qiu LX, Shen XK, Lv XJ, Qian XP, Song Y (2009) A meta-analysis of TP53 codon 72 polymorphism and lung cancer risk: evidence from 15,857 subjects. Lung Cancer 66:15–21PubMedCrossRefGoogle Scholar
  65. 65.
    Yan L, Zhang D, Chen C, Mao Y, Xie Y, Li Y, Huang Y, Han B (2009) TP53 Arg72Pro polymorphism and lung cancer risk: a meta-analysis. Int J Cancer 125:2903–2911PubMedCrossRefGoogle Scholar
  66. 66.
    Weston A, Godbold JH (1997) Polymorphisms of H-ras-1 and p53 in breast cancer and lung cancer: a meta-analysis. Environ Health Perspect 105:919PubMedGoogle Scholar
  67. 67.
    Rodin S, Rodin A (2000) Human lung cancer and p53: the interplay between mutagenesis and selection. Proc Natl Acad Sci USA 97:12244PubMedCrossRefGoogle Scholar
  68. 68.
    Salanti G, Sanderson S, Higgins JP (2005) Obstacles and opportunities in meta-analysis of genetic association studies. Genet Med 7:13–20PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Cancer InstituteFudan University Shanghai Cancer CenterShanghaiPeople’s Republic of China
  2. 2.State Key Laboratory of Genetic EngineeringInstitute of Genetics, School of Life Science, Fudan UniversityShanghaiPeople’s Republic of China
  3. 3.Institutes of Biomedical Sciences, Fudan UniversityShanghaiPeople’s Republic of China

Personalised recommendations